Boothbay Fund Management LLC Cuts Holdings in Enovis Co. (NYSE:ENOV)

Boothbay Fund Management LLC lessened its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 29.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 99,198 shares of the company's stock after selling 41,518 shares during the period. Boothbay Fund Management LLC owned about 0.17% of Enovis worth $4,353,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Enovis by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after buying an additional 75,348 shares in the last quarter. DAVENPORT & Co LLC boosted its stake in shares of Enovis by 6.0% in the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after purchasing an additional 157,216 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Enovis by 2.8% during the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after purchasing an additional 66,891 shares during the last quarter. River Road Asset Management LLC lifted its stake in Enovis by 3.8% in the 4th quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after purchasing an additional 45,762 shares during the last quarter. Finally, Boston Partners boosted its position in Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company's stock valued at $46,034,000 after buying an additional 223,816 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Stock Performance

NYSE:ENOV traded up $0.77 during trading hours on Friday, reaching $35.37. The stock had a trading volume of 321,022 shares, compared to its average volume of 756,892. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $53.91. The stock has a 50 day simple moving average of $35.79 and a 200 day simple moving average of $41.82. The stock has a market cap of $2.02 billion, a P/E ratio of -16.15 and a beta of 1.86. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, research analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.